ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO291

Sulfadiazine Induced Crystalluria

Session Information

  • Trainee Case Reports - VI
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Trainee Case Reports

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Chedid, Alice, Johns Hopkins University School of Medicine, Division of Nephrology, Baltimore, Maryland, United States
  • Hanouneh, Mohamad A., Johns Hopkins University School of Medicine, Division of Nephrology, Baltimore, Maryland, United States
  • Greenberg, Keiko I., Johns Hopkins University School of Medicine, Division of Nephrology, Baltimore, Maryland, United States
Introduction

Crystal-induced acute kidney injury (AKI) is caused by the intratubular precipitation of crystals, which results in obstruction. Crystal-induced AKI mostly occurs as a result of acute uric acid nephropathy and following the administration of drugs or toxins that are poorly soluble.

Case Description

A 23 year-old man with history of untreated HIV presented with 1 week history of right sided weakness. HIV viral load was 274,000 copies/mL and absolute CD4 count was 2 /cu mm. Brain MRI showed bilateral ring enhancing lesions. Patient was started empirically on pyrimethamine 75 mg daily, sulfadiazine 1.5 g q6 hours and leucovorin 25 mg daily. Brain biopsy confirmed the diagnosis of toxoplasmosis. Hospital course was complicated by AKI 8 days after starting this regimen. Labs revealed BUN 12 mg/dL and serum creatinine 2.0 mg/dL (baseline 0.8 mg/dL). Urinalysis showed no hematuria or pyuria; pH was 6. Urine protein/creatinine ratio was 0.42 g/g. Kidney ultrasound showed non-obstructing bilateral ureteral stones. Examination of urine sediment under polarized light revealed multiple yellow brown asymmetric rosette shaped crystals (sulfonamide crystals) (figure 1). Sulfadiazine was discontinued and patient was switched to clindamycin. Patient was treated with IV fluids (sodium bicarbonate) to alkalinize the urine (urine pH goal was > 7 with urine output goal was 2 L/day). The patient’s serum creatinine returned to baseline within 8 days.

Discussion

Sulfadiazine induced crystalluria is a serious complication in patients with AIDS who are treated for toxoplasmosis. Predisposing factors include high dose of sulfadiazine and volume depletion. It usually presents with AKI within 3 weeks of starting the medication. Treatment requires stopping the offending agent, aggressive IV hydration (UOP at least 1.5 L/day) and bicarbonate infusion to alkaline the urine (goal pH > 7).